Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Macro Group Pharmaceuticals (Macro Capital) S.A.E: Strengths and Weaknesses

  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: Macro Group Pharmaceuticals (Macro Capital) S.A.E
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Rating Financials

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

-

Rating Revisions

Macro Group Pharmaceuticals (Macro Capital) S.A.E SectorEgypt

Financial revisions

Revenue revisions (1 year)

-

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
97.24M - - - - -
1,056B
A
645B
BBB
465B
AAA
-
368B
A
335B
AA
275B
AAA
255B
A
229B
A
188B
AA
Average 381.59B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. MCRO Stock
  4. Ratings Macro Group Pharmaceuticals (Macro Capital) S.A.E